Shanghai Innostar Biotechnology Past Earnings Performance
Past criteria checks 1/6
Shanghai Innostar Biotechnology has been growing earnings at an average annual rate of 28.4%, while the Life Sciences industry saw earnings growing at 19.5% annually. Revenues have been growing at an average rate of 15.4% per year. Shanghai Innostar Biotechnology's return on equity is 9.9%, and it has net margins of 15.8%.
Key information
28.4%
Earnings growth rate
19.8%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 15.4% |
| Return on equity | 9.9% |
| Net Margin | 15.8% |
| Next Earnings Update | 30 Oct 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai Innostar Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,117 | 176 | 181 | 58 |
| 31 Mar 24 | 1,078 | 185 | 181 | 58 |
| 31 Dec 23 | 1,038 | 194 | 181 | 58 |
| 30 Jun 23 | 969 | 204 | 94 | 27 |
| 31 Mar 23 | 916 | 169 | 134 | 38 |
| 31 Dec 22 | 863 | 135 | 173 | 50 |
| 31 Dec 21 | 582 | 95 | 123 | 27 |
| 31 Dec 20 | 334 | 49 | 68 | 19 |
| 31 Dec 19 | 245 | 36 | 57 | 12 |
Quality Earnings: 688710 has a high level of non-cash earnings.
Growing Profit Margin: 688710's current net profit margins (15.8%) are lower than last year (21%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688710's earnings have grown significantly by 28.4% per year over the past 5 years.
Accelerating Growth: 688710's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688710 had negative earnings growth (-13.4%) over the past year, making it difficult to compare to the Life Sciences industry average (-7.5%).
Return on Equity
High ROE: 688710's Return on Equity (9.9%) is considered low.